Introduction
============

Since the 1970s, the idea that forced expiratory volume in 1-second (FEV~1~) decline accelerates with age has been generally accepted. Fletcher and Peto[@b1-copd-11-051] suggested a model of lung function decline across the lifespan of an individual -- the Fletcher--Peto curve. The Fletcher--Peto curve, which was obtained by extrapolating data from 792 men aged 30--59 years working in West London, showed that the rate of FEV~1~ decline accelerates slightly with age. Another cohort study, including participants from six eastern and midwestern cities in the United States, reported that the annual rate of FEV~1~ decline increased more rapidly with age in never smokers.[@b2-copd-11-051]

Based on the Fletcher--Peto curve, FEV~1~ decline among COPD patients typically occurs more quickly than FEV~1~ decline among smoking non-COPD patients. At the same time, recent studies have showed the rate of FEV~1~ decline is highly variable among COPD patients.[@b3-copd-11-051],[@b4-copd-11-051] The Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) observational study reported a wide range of annual change in FEV~1~, from a decrease of more than 40 mL to an increase of more than 20 mL, among COPD patients.[@b4-copd-11-051]

Many factors contributing to rapid FEV~1~ decline have been suggested among COPD patients. Previous studies reported that rates of decline were associated with smoking status,[@b4-copd-11-051]--[@b6-copd-11-051] exposure to biomass,[@b7-copd-11-051] experience of acute exacerbation,[@b4-copd-11-051],[@b5-copd-11-051] bronchodilator (BD) reversibility,[@b4-copd-11-051] presence of emphysema,[@b4-copd-11-051] and body mass index (BMI).[@b3-copd-11-051] However, there is controversy about whether lung function decline accelerates with age among COPD patients, although age has been recognized as a factor contributing to rapid decline of FEV~1~.

The ECLIPSE observational study did not demonstrate an increasing rate of FEV~1~ decline with an increase in age among COPD patients.[@b4-copd-11-051] Another study reported that "rapid" decliners were significantly younger than "slow" decliners.[@b3-copd-11-051] More recent data showed a decline of lung function among younger patients with COPD was similar to that of older patients.[@b8-copd-11-051],[@b9-copd-11-051] However, these studies did not include patients with Global initiative for Chronic Obstructive Lung Disease (GOLD) stage I for FEV~1~ decline analysis,[@b3-copd-11-051],[@b4-copd-11-051] nor did they include all ages of COPD patients. Moreover, previous studies compared "rapid" with "slow" decliners, defined by extremes of distribution among individual rates of decline.

Therefore, it is still unclear whether age is a real factor influencing the rate of FEV~1~ decline among COPD patients. The objective of this study is to evaluate the differences of annual FEV~1~ decline among COPD patients of different ages.

Materials and methods
=====================

Subjects
--------

We enrolled the COPD patients who were followed up at two tertiary care university hospitals -- the Seoul National University Hospital and Seoul National University Bundang Hospital -- during the period from January 2000 to August 2013.

All COPD diagnoses were confirmed with spirometry, defined by post-BD FEV~1~/FVC less than 0.7. The COPD patients above 40 years of age were included if they had performed more than two spirometries, including BD response, during follow-up. Patients with lung cancer or a history of lung resection surgery were excluded.

Study design
------------

A retrospective cohort study was performed. The study was reviewed and approved by the Institutional Review Board of both institutions and was performed in accordance with Good Clinical Practice guidelines (IRB number: H-1309-107-523, B-1406/212-105). The IRB granted a waiver of informed consent for our retrospective study.

Demographic and clinical data were collected from medical records. Serial measurements of spirometric values were collected during follow-up period. Both absolute and predicted values of spirometry were collected. The predicted values of FVC and FEV~1~ were calculated by published formula for Korean people, because when compared with predicted values for Caucasian populations, the predicted values were comparable or higher.[@b10-copd-11-051] Positive BD responsiveness was defined as more than 12% increase in FEV~1~, and more than 200 mL increase in FEV~1~.[@b11-copd-11-051]

The participants were categorized according to age as follow: below versus above the median age or four quartiles. Primary outcome was annual decline rate of post-BD FEV~1~ according to age, and secondary outcome was pre-BD FEV~1~.

Additionally, we analyzed the annual decline rate of post-BD FEV~1~ in subgroup of individuals who satisfied a post-BD FEV~1~/FVC ratio below the lower limit of normal (LLN) due to concerns that some normal participants may be included in the older groups of this study when using fixed FEV~1~/FVC ratio.[@b12-copd-11-051]

Statistical analysis
--------------------

Continuous variables are presented as means (± standard deviaiton \[SD\]), and categorical variables are expressed as relative frequencies and percentages. Age groups were compared using the chi-square test for continuous variables, or Student's *t*-test for categorical variables. A two-tailed *P*-value less than 0.05 indicated statistical significance. Annual changes in pre- and post-BD FEV~1~ for each age group were assessed using a multilevel mixed-effects linear regression model. It was adjusted for sex, body mass index, smoking status (current smokers, formal smokers, or never smokers), bronchodilator response, experience of acute exacerbation, and initial FEV~1~.

Results
=======

Study subjects
--------------

Five hundred and eighteen patients with COPD were enrolled. Baseline characteristics and lung function are shown in [Table 1](#t1-copd-11-051){ref-type="table"}. Among 518 participants, 94.2% of patients were male, and their median age was 67 years (range, 42--90 years). Mean absolute and predicted values of post-BD FEV~1~ were 1.57±0.62 L and 52.53%±18.29%, respectively. On the basis of FEV~1~ severity using GOLD grade,[@b13-copd-11-051] 8.7%, 44.8%, 37.3%, and 9.3% of patients distributed GOLD I, II, III, and IV, respectively. Mean duration of observation was 55.08±28.00 months. Mean frequency of pulmonary function test was 0.57±0.29/year.

Annual rate of FEV~1~ decline in patients above versus below median age
-----------------------------------------------------------------------

To evaluate whether FEV~1~ decline is accelerated among older COPD patients, we first categorized patients into two groups above and below the median age of 67 years. COPD patients below the median age had lower BMI, more significant smoking history, and less experience of acute exacerbation than those above median age ([Table 1](#t1-copd-11-051){ref-type="table"}). The distribution of FEV~1~ severity by GOLD stage was not significantly different between two groups (*P*=0.848). Therefore, the annual rate of FEV~1~ decline among the two groups was compared after adjustment of the following covariates: sex, height, BMI, smoking status, experience of acute exacerbation, presence of BD response, and initial FEV~1~. Post-BD FEV~1~ declined more rapidly among older patients (−13.01±4.10 mL/year versus −25.04±4.01 mL/year, respectively, *P*=0.036), even when expressed as the predictive value in FEV~1~ (−0.40%±0.12%/year versus −0.90%±0.12%/year, respectively, *P*=0.003). The rate of pre-BD FEV~1~ decline was also faster among older patients, but less steep than that of post-BD FEV~1~ ([Table 2](#t2-copd-11-051){ref-type="table"}).

Annual rate of FEV~1~ decline in quartiles of age
-------------------------------------------------

Next, participants were divided into quartiles based on age. The numbers and ages of patients within each quartile group were as follows: Q1 (n=128, below 63 years), Q2 (n=107, 63--67 years), Q3 (n=141, 67--72 years), and Q4 (n=142, above 72 years). The distribution of FEV~1~ severity by GOLD was not different between age groups (*P*=0.490) ([Table S1](#SD1-copd-11-051){ref-type="supplementary-material"}). The annual rate of FEV~1~ decline was also compared after adjustment of covariates. Annual decline in post-BD FEV~1~ increased with increasing age, whether expressed as absolute value (−10.60±5.57 mL/year, −15.84±6.01 mL/year, −18.63±5.53 mL/year, −32.94±6.01 mL/year, respectively, *P*=0.048) or predicted value (−0.34%±0.19%/year, −0.53%±0.21%/year, −0.62%±0.19%/year, −1.26%±0.21%/year, respectively, *P*=0.010) ([Table 3](#t3-copd-11-051){ref-type="table"}).

Annual rate of FEV~1~ decline in subjects meeting the LLN criterion
-------------------------------------------------------------------

Among 518 patients, 481 patients had post-BD FEV~1~/FVC ratio below the LLN. When patients were categorized according to median age, there was a trend toward greater FEV~1~ decline with age (−13.17±4.19 mL/year versus −23.15±4.13 mL/year, *P*=0.062) ([Table 4](#t4-copd-11-051){ref-type="table"}). When FEV~1~ was expressed as a percentage of the predictive value, post-BD FEV~1~ declined more rapidly in older patients (−0.40%±0.15%/year versus −0.83%±0.14%/year, respectively, *P*=0.039). Dividing participants into quartile groups based on age demonstrated consistent results whether expressed as absolute value (−11.11±6.03 mL/year, −13.17±5.79 mL/year, −16.67±5.47 mL/year, −31.43±6.28 mL/year, respectively, *P*=0.085), or predicted value (−0.34%±0.21%/year, −0.46%±0.20%/year, −0.55%±0.19%/year, −1.20%±0.22%/year, respectively, *P*=0.023).

Discussion
==========

Previous studies showed an accelerated decline in FEV~1~ with age among healthy participants. A prospective epidemiological study by Fletcher and Peto,[@b1-copd-11-051] which evaluated 1,136 working men aged 35--59 years over an 8-year follow-up period, demonstrated that FEV~1~ falls gradually over a lifetime, and the rate of FEV~1~ decline accelerates slightly with age. Ware et al[@b2-copd-11-051] reported that annual rate of FEV~1~ decline was higher among elderly non-smokers: 12.9 mL/year at age 25 years versus 58.2 mL/year at age 75 years. In more recent cross-sectional and longitudinal studies, an accelerated decline in FEV~1~ with age was also reported in never-smoker patients.[@b14-copd-11-051],[@b15-copd-11-051] Sandford et al[@b16-copd-11-051] reported that among smokers, rapid decline was associated with older age compared with non-decline. These results suggest an accelerated decline of FEV~1~ with aging among non-COPD patients.

Thus, it can be speculated that decline of FEV~1~ among COPD patients is also accelerated with age. However, it has not been clear whether FEV~1~ is also accelerated among aged COPD patients compared with young COPD patients. Recent studies have not demonstrated that the rate of FEV~1~ decline accelerates with age among COPD patients. Casanova et al[@b3-copd-11-051] defined decliners with significant slope as patients showing a statistically significant annual loss of FEV~1~ (−86 mL/year; 95% confidence interval, −32 to −278 mL/year) and decliners with nonsignificant slope as those who demonstrated a nonstatistically significant annual FEV~1~ decline (−28 mL/year; 95% confidence interval, +9 to −214 mL/year). They demonstrated that rapid decliners with significant slope were younger, compared with nonstatistically significant slope decliners (64±9 years versus 66±9 years, *P*=0.018, respectively). However, unlike our study, they categorized participants according to the rate of FEV~1~ decline and not by age, which may have affected the results. In addition, the proportion of decliner with significant slope was small (18%), and the range of annual rate of FEV~1~ decline in our study was approximately 10--33 mL/year, which is much lower than that of significant slope decliners in the previous study. These factors may also have influenced the results. Furthermore, Casanova et al[@b3-copd-11-051] also reported that rapid decliners had a lower BMI and better lung function at baseline. However, after multivariate logistic regression including age, sex, pack-years, smoking habit, comorbidity, and annual hospital exacerbation rate, higher level of FEV~1~ and low BMI at baseline were the only two independent and significant predictors of FEV~1~ decline and they failed to show association between age and FEV~1~ decline.

In contrast, Nishimura et al[@b8-copd-11-051] reported that mean age was not significantly different between rapid decliner and slow decliner (69±6 years versus 70±8 years, *P*=0.11, respectively). This trial had limitation and categorized all patients into only three groups by rate of FEV~1~ decline. Vestbo et al[@b4-copd-11-051] reported that age was not associated with the rate of decline of FEV~1~ in the ECLIPSE cohort. However, this study did not include COPD patients with GOLD stage I disease. A more recent study evaluated progression of FEV~1~ among younger (≤55 years) and older (≥65 years) COPD patients.[@b9-copd-11-051] They reported that average annual rate of FEV~1~ decline was similar among younger and older COPD patients (38.8 mL/year versus 40.6 mL/year, respectively; *P*=0.86). In this study, the proportion of GOLD stage I was higher among younger COPD patients. It could affect the rate of FEV~1~ decline because it appears to be inversely related to the GOLD stage.[@b17-copd-11-051],[@b18-copd-11-051] Moreover, COPD patients between the ages of 55 years and 65 years were not included. Different results in these studies might be due to different inclusion criteria.

When compared with previous trials, our study included all COPD patients between the ages of 42 and 90 years. GOLD stage I COPD patients were also included in our study, and the distribution of GOLD stage and predictive values of FEV~1~ were not different between age groups. To minimize the effect of arbitrary categorization of age groups on the rate of FEV~1~ decline, participants were categorized according to age by two different criteria: median age and quartiles of age. After categorizing patients into age groups based on median age or quartile, acceleration of FEV~1~ decline with aging was observed.

Additionally, we performed further analysis categorizing patients into groups with 10-year intervals ([Table S2](#SD2-copd-11-051){ref-type="supplementary-material"}). When the data were expressed as predictive values, the rate of decline of the mean post-BD FEV~1~ was significantly faster among older patients, when compared with younger patients (−0.39%±0.80%/year, −0.24%±0.24%/year, −0.61%±0.14%/year, −0.83%±0.19%/year, −2.00%±0.46%/year, respectively; *P*=0.015) ([Table S3](#SD3-copd-11-051){ref-type="supplementary-material"}). Only seven patients were allocated to the youngest age group, and it might explain why the 40- to 49-year-old group showed higher rates of FEV~1~ decline.

It could be argued that our results were the effect of regression-to-the-mean phenomenon. Regression-to-the-mean is the phenomenon that if a variable is extreme on its first measurement, it will tend to be closer to the average on its next measurement. In our study, although it did not reach statistical significance, older patients showed slightly higher proportion of GOLD III--IV ([Table 1](#t1-copd-11-051){ref-type="table"}), suggesting the possibility of better FEV~1~ in younger group. In fact, the absolute initial value of FEV~1~ was higher in the younger group than that in the older group ([Tables 1](#t1-copd-11-051){ref-type="table"}, [S1](#SD1-copd-11-051){ref-type="supplementary-material"}, and [S2](#SD2-copd-11-051){ref-type="supplementary-material"}). Thus, according to regression-to-the-mean, higher initial FEV~1~ value in younger patients would be followed by the lower FEV~1~ value on next measurement, resulting in more rapid decline of FEV~1~ compared with older patients. However, our result is opposite, that is, faster FEV~1~ decline in older groups. Therefore, our result of faster FEV~1~ decline in younger group seems less likely to be due to regression-to-the-mean phenomenon.

Absolute value of FEV~1~ has been conventionally used for analysis of lung function decline in COPD patients.[@b3-copd-11-051],[@b4-copd-11-051],[@b8-copd-11-051],[@b9-copd-11-051],[@b19-copd-11-051] However, the Toward a Revolution in COPD Health (TORCH) study demonstrated that the trend of FEV~1~ decline was preserved when FEV~1~ decline was expressed as predictive value.[@b20-copd-11-051] In this study, the rate of FEV~1~ decline was expressed not only as absolute value, but also as predictive value. Change of absolute value of FEV~1~ could be underestimated in older patients, because absolute value of FEV~1~ among old patients was lower than among younger patients. Therefore, predictive value of FEV~1~ could be a more appropriate measure of the decline of FEV~1~ than absolute value. Thomsen et al[@b21-copd-11-051] reported that relative changes of FEV~1~ seem to explain changes in lung function better than absolute measurement among heavy smokers.

We used pre-BD FEV~1~, as well as post-BD FEV~1~, to evaluate the rate of decline in FEV~1~. Interestingly, the rate of decline of the post-BD FEV~1~ was higher than that of pre-BD FEV~1~ among all age groups. This observation is consistent with findings in previous studies.[@b22-copd-11-051],[@b23-copd-11-051] Tashkin et al[@b23-copd-11-051] reported that the slopes of post-BD FEV~1~ were significantly steeper than the slopes calculated from the pre-BD measurements. In addition, post hoc analysis of data from the Long-Term Impacts on Function with Tiotropium (UPLIFT) trial demonstrated that FEV~1~ response to bronchodilators declined significantly over time, and the rate of FEV~1~ decline was generally more significant among older patients. Development of tolerance to bronchodilator therapy over the course of the disease could be an explanation for the rapid decline in post-BD lung function.[@b24-copd-11-051]

Our study has some limitations. First of all, as our study design was retrospective, we could not directly evaluate the effect of treatment regimens. Instead, because prescribed medications vary as the years go by, we analyzed the rate of FEV~1~ decline in each group by adding "year of diagnosis" as variable for adjustment. When patients were categorized into quartiles, the annual decline in post-BD FEV~1~ was still accelerated with age, whether expressed as absolute value or predicted value. Next, over-adjustment for baseline FEV~1~ may be of concern. However, this method has already been used in previous studies including a post hoc analysis of the TORCH study.[@b20-copd-11-051] Third, patients with spirometries at irregular intervals were excluded, which might have introduced a selection bias. However, excluding irregular spirometries could also decrease bias because it is possible that spirometries were performed irregularly during an acute event.

Despite some of the aforementioned limitations, to our knowledge, this is the first study that includes COPD patients of all ages and all GOLD severity stages to evaluate the annual decline of FEV~1~ across age groups. This study demonstrated that the rate of decline among both post-BD and pre-BD FEV~1~ groups accelerated with age, conceptually in accordance with the Fletcher--Peto curve.

Conclusion
==========

Conceptually, in accordance with the Fletcher--Peto curve, annual rates of FEV~1~ decline, whether expressed as absolute or predictive values, accelerate with increasing age among patients with COPD.

Supplementary materials
=======================

###### 

Baseline characteristics according to age quartile

                                  Q1 (below 63 years, n=128)   Q2 (63--67 years, n=107)   Q3 (67--72 years, n=141)   Q4 (above 72 years, n=142)   *P*-value
  ------------------------------- ---------------------------- -------------------------- -------------------------- ---------------------------- -----------
  Sex, male                       123 (96.1)                   102 (95.3)                 132 (93.6)                 131 (92.3)                   0.145
  BMI, kg/m^2^                    23.49±2.93                   22.88±3.16                 22.20±3.51                 21.71±3.26                   \<0.001
  Smoking status                                                                                                                                  0.407
   Current smoker                 76 (59.4)                    41 (38.3)                  54 (38.3)                  48 (33.8)                    
   Former smoker                  35 (27.3)                    52 (48.6)                  62 (44.0)                  75 (58.2)                    
   Never smoker                   9 (7.0)                      5 (4.7)                    8 (5.7)                    11 (7.7)                     
   Unknown                        8 (6.3)                      9 (8.4)                    17 (12.1)                  8 (5.6)                      
  Pack-year                       39.65±20.80                  41.66±17.55                45.92±23.13                45.89±25.77                  0.051
  GOLD                                                                                                                                            0.490
   I                              12 (9.4)                     12 (11.2)                  7 (5.0)                    14 (9.9)                     
   II                             58 (45.3)                    44 (41.1)                  61 (43.3)                  69 (48.6)                    
   III                            43 (33.6)                    42 (39.3)                  56 (39.7)                  52 (36.6)                    
   IV                             15 (11.7)                    9 (8.4)                    17 (12.1)                  7 (4.9)                      
  Post-bronchodilator                                                                                                                             
   FVC, L                         3.68±0.85                    3.47±0.83                  3.10±0.75                  3.10±0.84                    \<0.001
   FVC, %                         83.62±16.74                  82.88±17.31                76.73±15.78                79.10±16.46                  0.002
   FEV~1~, L                      1.81±0.69                    1.65±0.64                  1.41±0.52                  1.44±0.53                    \<0.001
   FEV~1~, %                      53.27±18.86                  53.16±18.79                48.92±16.79                55.32±18.41                  0.027
   FEV~1~/FVC, %                  48.52±11.97                  46.93±12.21                45.53±11.05                46.51±11.17                  0.203
  Pre-bronchodilator                                                                                                                              
   FVC, L                         3.49±0.91                    3.31±0.88                  2.95±0.76                  2.97±0.82                    \<0.001
   FVC, %                         79.20±18.22                  78.91±18.81                73.08±16.33                75.78±17.69                  0.016
   FEV~1~, L                      1.69±0.72                    1.53±0.65                  1.31±0.52                  1.35±0.53                    \<0.001
   FEV~1~, %                      49.70±19.64                  49.34±19.28                45.17±16.82                51.71±18.70                  0.027
   FEV~1~/FVC, %                  47.45±12.09                  45.54±12.37                44.15±10.78                45.39±11.10                  0.135
  Positive BDR                    2 (1.6)                      8 (7.5)                    7 (5.0)                    7 (4.9)                      0.335
  History of acute exacerbation   26 (20.3)                    37 (34.6)                  47 (33.3)                  64 (45.1)                    \<0.001
  Follow-up months                61.32±30.80                  59.66±26.33                56.63±26.10                44.38±25.56                  \<0.001

**Note:** Data presented as mean ± SD or n (%).

**Abbreviations:** BDR, bronchodilator response; BMI, body mass index; FEV~1~, forced expiratory volume in 1-second; FVC, forced vital capacity; GOLD, Global initiative for Chronic Obstructive Lung Disease.

###### 

Baseline characteristics: 40--90 years of age

                                  40--49 (n=7)   50--59 (n=77)   60--69 (n=241)   70--79 (n=159)   80--90 (n=32)   *P*-value
  ------------------------------- -------------- --------------- ---------------- ---------------- --------------- -----------
  Sex, male                       7 (100)        77 (97.5)       227 (94.2)       150 (94.3)       27 (84.4)       0.145
  BMI, kg/m^2^                    20.86±3.28     23.57±2.82      22.84±3.37       21.72±3.07       21.94±3.94      \<0.001
  Smoking                                                                                                          0.253
   Current smoker                 3 (42.9)       47 (59.5)       105 (43.6)       57 (35.8)        7 (21.9)        
   Former smoker                  3 (42.9)       22 (27.8)       102 (42.3)       78 (49.1)        19 (59.4)       
   Never smoker                   1 (14.3)       4 (5.1)         13 (5.4)         10 (6.3)         5 (15.6)        
   Unknown                        0 (0)          6 (7.6)         21 (8.7)         14 (8.8)         1 (3.1)         
  Pack-year                       29.80±16.88    41.77±20.46     42.98±20.61      46.51±25.42      39.43±24.15     0.129
  GOLD                                                                                                             0.219
   I                              0 (0)          7 (8.9)         20 (8.3)         16 (10.1)        2 (6.3)         
   II                             3 (42.9)       34 (43.0)       110 (45.6)       67 (42.1)        18 (56.3)       
   III                            3 (42.9)       29 (36.7)       85 (35.3)        65 (40.9)        11 (34.4)       
   IV                             1 (14.3)       9 (11.4)        26 (10.8)        11 (6.9)         1 (3.1)         
  Post-bronchodilator                                                                                              
   FVC, L                         3.58±0.47      3.72±0.81       3.35±0.85        3.18±0.78        2.75±0.75       \<0.001
   FVC, %                         80.71±11.73    83.43±15.89     80.91±17.35      79.01±16.67      75.09±13.81     0.128
   FEV~1~, L                      1.84±0.60      1.81±0.68       1.59±0.63        1.46±0.54        1.25±0.42       \<0.001
   FEV~1~, %                      50.57±17.06    52.14±18.04     52.17±18.56      53.09±18.65      55.41±15.81     0.890
   FEV~1~/FVC, %                  51.57±13.59    44.77±11.04     46.99±12.10      46.01±11.15      46.28±10.71     0.625
  Pre-bronchodilator                                                                                               
   FVC, L                         3.40±0.53      3.53±0.89       3.19±0.88        3.04±0.80        2.60±0.76       \<0.001
   FVC, %                         76.71±12.69    79.06±17.75     77.01±18.32      75.62±17.63      71.22±15.70     0.285
   FEV~1~, L                      1.76±0.61      1.69±0.71       1.47±0.64        1.37±0.54        1.17±0.40       \<0.001
   FEV~1~, %                      48.14±17.31    48.68±19.10     48.29±18.88      49.58±19.07      51.53±14.92     0.891
   FEV~1~/FVC, %                  50.86±13.07    46.80±11.30     46.80±11.30      45.54±12.06      44.86±11.23     0.568
  Positive BDR                    0 (0)          1 (1.3)         14 (5.8)         9 (5.7)          1 (0)           0.621
  History of acute exacerbation   2 (28.6)       16 (20.3)       76 (31.5)        60 (37.7)        20 (62.5)       \<0.001
  Follow-up months                58.72±24.08    63.38±31.35     57.51±26.95      49.93±26.66      40.75±25.97     \<0.001

**Note:** Data presented as mean ± SD or n (%).

**Abbreviations:** BDR, bronchodilator response; BMI, body mass index; FEV~1~, forced expiratory volume in 1-second; FVC, forced vital capacity; GOLD, Global initiative for Chronic Obstructive Lung Disease.

###### 

Lung function decline: 40--90 years of age

                         Unadjusted     Adjusted                  
  ---------------------- -------------- ---------- -------------- ---------------------------------------------------
  FEV~1~, mL/year                                                 
   Post-bronchodilator                                            
    40--49               2.14±20.34     0.123      −10.49±23.06   0.136[a](#tfn16-copd-11-051){ref-type="table-fn"}
    50--59               −7.34±5.97                −7.03±6.96     
    60--69               −18.52±3.59               −18.65±4.09    
    70--79               −24.51±4.83               −23.93±5.39    
    80--90               −31.44±11.89              −42.26±13.32   
   Pre-bronchodilator                                             
    40--49               3.79±20.43     0.079      −11.08±23.47   0.152[a](#tfn16-copd-11-051){ref-type="table-fn"}
    50--59               −2.38±5.89                −2.00±7.05     
    60--69               −11.49±3.58               −11.12±4.17    
    70--79               −21.70±4.85               −20.24±5.52    
    80--90               −25.16±11.94              −33.96±13.66   
  FEV~1~, %/year                                                  
   Post-bronchodilator                                            
    40--49               −0.01±0.67     0.015      −0.39±0.80     0.015[b](#tfn17-copd-11-051){ref-type="table-fn"}
    50--59               −0.23±0.20                −0.24±0.24     
    60--69               −0.62±0.12                −0.61±0.14     
    70--79               −0.87±0.16                −0.83±0.19     
    80--90               −1.52±0.39                −2.00±0.46     
   Pre-bronchodilator                                             
    40--49               0.08±0.67      0.006      −0.33±0.79     0.020[b](#tfn17-copd-11-051){ref-type="table-fn"}
    50--59               −0.08±0.19                −0.07±0.24     
    60--69               −0.40±0.12                −0.37±0.14     
    70--79               −0.83±0.16                −0.75±0.19     
    80--90               −1.28±0.39                −1.62±0.46     

**Notes:**

The numbers of patients within each group were as follows: 40--49 years (n=7), 50--59 years (n=77), 60--69 years (n=241), 70--79 years (n=159) and ≥80 years (n=32). Adjusted for sex, body mass index, smoking status, bronchodilator response, experience of acute exacerbation, and initial FEV~1~.

Adjusted for smoking status, bronchodilator response, experience of acute exacerbation, and initial FEV~1~.

**Abbreviations:** FEV~1~, forced expiratory volume in 1-second; SE, standard error.
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###### 

Baseline characteristics: below versus above the median age of 67 years

                                  Total patients (n=518)   Younger patients (n=235)   Older patients (n=283)   *P*-value
  ------------------------------- ------------------------ -------------------------- ------------------------ -----------
  Sex, male                       488 (94.2)               225 (95.7)                 263 (92.9)               0.173
  BMI, kg/m^2^                    22.52±3.30               23.21±3.04                 21.95±3.39               \<0.001
  Smoking status                                                                                               
   Current smoker                 219 (42.3)               117 (49.8)                 102 (36.0)               0.008
   Former smoker                  224 (43.2)               87 (37.0)                  137 (48.4)               
   Never smoker                   33 (6.4)                 14 (6.0)                   19 (6.7)                 
   Unknown                        42 (8.1)                 17 (7.2)                   25 (8.9)                 
  Pack-year                       43.48±22.43              40.57±19.37                45.90±24.45              0.006
  GOLD                                                                                                         0.848
   I                              45 (8.7)                 24 (10.2)                  21 (7.4)                 
   II                             232 (44.8)               102 (43.4)                 130 (45.9)               
   III                            193 (37.3)               85 (32.6)                  108 (38.2)               
   IV                             48 (9.3)                 24 (10.2)                  24 (8.5)                 
  Post-bronchodilator                                                                                          
   FVC, L                         3.32±0.84                3.59±0.85                  3.10±0.77                \<0.001
   FVC, %                         80.35±16.72              83.28±16.97                77.92±16.14              \<0.001
   FEV~1~, L                      1.57±0.62                1.74±0.67                  1.43±0.53                \<0.001
   FEV~1~, %                      52.53±18.29              53.22±18.79                52.13±17.88              0.501
   FEV~1~/FVC, %                  46.83±11.58              47.80±12.08                46.02±11.10              0.082
  Pre-bronchodilator                                                                                           
   FVC, L                         3.16±0.88                3.41±0.90                  2.95±0.80                \<0.001
   FVC, %                         76.53±17.83              79.06±18.45                74.43±17.05              0.003
   FEV~1~, L                      1.46±0.62                1.62±0.69                  1.33±0.52                \<0.001
   FEV~1~, %                      48.94±18.69              49.54±19.44                48.45±18.06              0.514
   FEV~1~/FVC, %                  45.59±11.56              46.58±12.22                44.77±10.94              0.079
  Positive BDR                    24 (4.6)                 10 (4.3)                   14 (4.9)                 0.709
  History of acute exacerbation   174 (33.6)               63 (26.8)                  111 (39.2)               0.003
  Follow-up months                55.08±28.00              60.57±28.80                50.53±26.52              \<0.001

**Note:** Data presented as mean ± SD or n (%).

**Abbreviations:** BDR, bronchodilator response; BMI, body mass index; FEV~1~, forced expiratory volume in 1-second; FVC, forced vital capacity; GOLD, Global initiative for Chronic Obstructive Lung Disease.

###### 

Lung function decline: below versus above the median age of 67 years

                         Unadjusted    Adjusted                 
  ---------------------- ------------- ---------- ------------- --------------------------------------------------
  FEV~1~, mL/year                                               
   Post-bronchodilator                                          
    Younger              −12.60±3.56   0.021      −13.01±4.10   0.036[a](#tfn3-copd-11-051){ref-type="table-fn"}
    Older                −24.24±3.57              −25.04±4.01   
   Pre-bronchodilator                                           
    Younger              −6.45±3.53    0.009      −6.97±3.79    0.022[a](#tfn3-copd-11-051){ref-type="table-fn"}
    Older                −19.55±3.57              −19.22±3.79   
  FEV~1~, %/year                                                
   Post-bronchodilator                                          
    Younger              −0.42±0.11    0.004      −0.40±0.12    0.003[b](#tfn4-copd-11-051){ref-type="table-fn"}
    Older                −0.90±0.12               −0.90±0.12    
   Pre-bronchodilator                                           
    Younger              −0.22±0.12    0.001      −0.21±0.14    0.008[b](#tfn4-copd-11-051){ref-type="table-fn"}
    Older                −0.76±0.12               −0.74±0.14    

**Notes:**

Adjusted for sex, body mass index, smoking status, bronchodilator response, experience of acute exacerbation, and initial FEV~1~.

Adjusted for smoking status, bronchodilator response, experience of acute exacerbation, and initial FEV~1~.

**Abbreviations:** FEV~1~, forced expiratory volume in 1-second; SE, standard error.

###### 

Lung function decline according to age quartile

                         Unadjusted    Adjusted                 
  ---------------------- ------------- ---------- ------------- --------------------------------------------------
  FEV~1~, mL/year                                               
   Post-bronchodilator                                          
    Q1                   −10.62±4.84   0.048      −10.60±5.57   0.048[a](#tfn6-copd-11-051){ref-type="table-fn"}
    Q2                   −14.82±5.24              −15.84±6.01   
    Q3                   −19.71±4.71              −18.63±5.53   
    Q4                   −30.34±5.46              −32.94±6.01   
   Pre-bronchodilator                                           
    Q1                   −4.99±4.78    0.029      −4.91±5.66    0.044[a](#tfn6-copd-11-051){ref-type="table-fn"}
    Q2                   −8.17±5.21               −8.09±6.10    
    Q3                   −15.26±4.69              −13.78±5.45   
    Q4                   −25.45±5.50              −27.35±6.18   
  FEV~1~, %/year                                                
   Post-bronchodilator                                          
    Q1                   −0.33±0.16    0.005      −0.34±0.19    0.010[b](#tfn7-copd-11-051){ref-type="table-fn"}
    Q2                   −0.50±0.17               −0.53±0.21    
    Q3                   −0.68±0.16               −0.62±0.19    
    Q4                   −1.17±0.18               −1.26±0.21    
   Pre-bronchodilator                                           
    Q1                   −0.18±0.16    0.002      −0.17±0.19    0.007[b](#tfn7-copd-11-051){ref-type="table-fn"}
    Q2                   −0.28±0.17               −0.27±0.21    
    Q3                   −0.54±0.15               −0.47±0.18    
    Q4                   −1.04±0.18               −1.08±0.21    

**Notes:**

The numbers and ages of patients within each quartile group were as follows: Q1 (n=128, below 63 years), Q2 (n=107, 63--67 years), Q3 (n=141, 67--72 years), and Q4 (n=142, above 72 years). Adjusted for sex, body mass index, smoking status, bronchodilator response, experience of acute exacerbation, and initial FEV~1~.

Adjusted for smoking status, bronchodilator response, experience of acute exacerbation, and initial FEV~1~.

**Abbreviations:** FEV~1~, forced expiratory volume in 1-second; SE, standard error.

###### 

Annual rate of post-bronchodilator FEV~1~ decline in subjects meeting the lower limit of normal criterion

                              Unadjusted    Adjusted                 
  --------------------------- ------------- ---------- ------------- ---------------------------------------------------
  According to median age                                            
   FEV~1~, mL/year                                                   
    Younger                   −11.79±3.64   0.053      −13.17±4.19   0.062[a](#tfn9-copd-11-051){ref-type="table-fn"}
    Older                     −21.83±3.68              −23.15±4.13   
   FEV~1~, %/year                                                    
    Younger                   −0.39±0.12    0.017      −0.40±0.15    0.039[b](#tfn10-copd-11-051){ref-type="table-fn"}
    Older                     −0.80±0.12               −0.83±0.14    
  According to age quartile                                          
   FEV~1~, mL/year                                                   
    Q1                        −10.62±5.22   0.113      −11.11±6.03   0.085[a](#tfn9-copd-11-051){ref-type="table-fn"}
    Q2                        −12.87±5.05              −13.17±5.79   
    Q3                        −17.40±4.80              −16.67±5.47   
    Q4                        −28.12±5.70              −31.43±6.28   
   FEV~1~, %/year                                                    
    Q1                        −0.33±0.17    0.021      −0.34±0.21    0.023[b](#tfn10-copd-11-051){ref-type="table-fn"}
    Q2                        −0.50±0.17               −0.46±0.20    
    Q3                        −0.60±0.16               −0.55±0.19    
    Q4                        −1.08±0.19               −1.20±0.22    

**Notes:**

The numbers and ages of patients within each quartile group were as follows: Q1 (n=107, below 62 years), Q2 (n=115, 62--67 years), Q3 (n=133, 67--72 years), and Q4 (n=126, above 72 years). Adjusted for sex, body mass index, smoking status, bronchodilator response, experience of acute exacerbation, and initial FEV~1~.

Adjusted for smoking status, bronchodilator response, experience of acute exacerbation, and initial FEV~1~.

**Abbreviations:** FEV~1~, forced expiratory volume in 1-second; SE, standard error.
